
Study determines retinal vein occlusion after COVID-19 vaccinations to be rare
A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.

FDA approves faricimab-svoa for the treatment of retinal vein occlusion

Faricimab maintained vision improvements with extended treatment intervals up to 4 months for people with retinal vein occlusion in phase III studies

A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.